Company intelligence / Profile preview

IntraGel Therapeutics

Nazareth, Northern District, Israelintra-gel.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Early clinical results with the SRGel platform delivering cisplatin locally to solid tumors have demonstrated safety and efficacy with minimal-to-no side effects. The company is pursuing a fast-track 505(b)(2) regulatory pathway for its lead product TumoCure in head and neck cancer. Preclinical data support broad compatibility of the platform with most FDA-approved anticancer agents. The company is raising funds to advance into Phase II trials.[1][4][5]

Therapeutic areas: Oncology
Modalities: Small molecules (notably cisplatin and potentially other anti-cancer drugs)Gel-based drug delivery systems[1][4][10]
Industry: Biotech

Drug pipeline

1 asset

TumoCure

Partnerships

Advanced collaboration stages with leading global pharmaceutical companies are mentioned but not named explicitly.[5]

Beyond the preview

Go deeper on IntraGel Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IntraGel Therapeutics.